Metformin is one of the most common drugs taken by type 2 diabetics to help combat insulin resistance. Researchers have recently found that it may have an added benefit: it slows the growth rate of prostate cancer.
A study conducted by Princess Margaret Hospital, Toronto was presented at an annual meeting of the American Association for Cancer Research. The study found that metformin not only slowed the growth of cancer but in some cases reduced the tumor.
A man's chance of developing prostate cancer increases with age. While genetics can play a role, two-thirds of all cases of prostate cancer occur in men age 65 and older.
“This research builds on the hypothesis that metformin has a rule in prostate cancer,” said Dr. Anthony M. Joshua, lead author of the study. “Exactly what that role will be will depend on the results of the analysis currently being completed by our study team and others worldwide.”